Drug discovery and clinical research by Lexicon Pharmaceuticals
Lexicon Pharmaceuticals to present new clinical data on type 1 diabetes and neuropathic pain in New Orleans
Lexicon Pharmaceuticals will present new data this week at the #ADASciSessions in New Orleans, focusing on its clinical programs in type 1 diabetes and diabetic peripheral neuropathic pain. The ...
Lexicon Pharmaceuticals to present pipeline updates at NYC healthcare investor event
Lexicon Pharmaceuticals announced plans to participate in the Jefferies Healthcare Conference in New York City next week. The company will engage with the healthcare investment community and share ...
Lexicon Pharmaceuticals: up to 50 percent of type 2 diabetes patients affected by painful neuropathy
An estimated 50 percent of individuals with type 2 diabetes and 30 percent of those with type 1 diabetes are impacted by painful diabetic peripheral neuropathy, according to Lexicon ...
Lexicon Pharmaceuticals management to join Nasdaq HQ fireside chat
Lexicon Pharmaceuticals announced it will participate in the HCWCO BioConnect Investor Conference this week. The company’s management team is scheduled to take part in a fireside chat on May ...
Lexicon Pharmaceuticals presents Phase 2b results supporting 10 mg dose in DPNP at AAN 2026
Lexicon Pharmaceuticals unveiled results from its Phase 2b PROGRESS trial at AAN 2026, supporting the advancement of a 10 mg dose into Phase 3 for diabetic peripheral neuropathic pain (DPNP). The ...
SONATA-HCM Phase 3 clinical trial accelerates HCM drug research for Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is moving forward with the SONATA-HCM Phase 3 clinical trial, focusing on its dual SGLT1/SGLT2 inhibitor for hypertrophic cardiomyopathy (HCM). The trial and broader HCM ...
Lexicon Pharmaceuticals joins Texas Life Sciences Summit to engage industry leaders and drive sector momentum
Lexicon Pharmaceuticals participated in the 2026 Texas Life Sciences Summit as a sponsor, connecting with leaders and innovators across the life sciences industry. The company reported a sense ...
Lexicon Pharmaceuticals unveils ACC26 trial analysis on BMI and cardiovascular outcomes
Lexicon Pharmaceuticals has presented new findings from the SCORED trial at ACC26, focusing on heart failure and cardiovascular outcomes among adults with type 2 diabetes and chronic kidney ...
Lexicon Pharmaceuticals unveils new SOTA‑P‑CARDIA Chapter 2 data in HFpEF at ACC26
Lexicon Pharmaceuticals presented fresh insights from the SOTA‑P‑CARDIA trial at the ACC26 meeting. Dr. Juan Badimon delivered Chapter 2 results, which build on previous findings and focus ...
ACC meeting features Lexicon Pharmaceuticals clinical research presentations
Lexicon Pharmaceuticals is set to unveil data from its clinical programs at the American College of Cardiology event this week. The company will present analyses from the SCORED and SOTA P CARDIA ...
Lexicon Pharmaceuticals advances chronic pain treatment options with focus on non opioid innovation
Lexicon Pharmaceuticals is intensifying efforts to expand treatment options for chronic pain, including diabetic peripheral neuropathic pain (DPNP), spotlighting the need for greater industry and ...
ACSL5 emerges as obesity treatment target, Lexicon Pharmaceuticals outlines
Lexicon Pharmaceuticals has published a recent study on the Journal of the Endocrine Society homepage, focusing on ACSL5 as a biological target in ongoing research for obesity and chronic weight ...
Lexicon Pharmaceuticals pushes for new treatments in hypertrophic cardiomyopathy community
Lexicon Pharmaceuticals is rallying support to raise awareness for hypertrophic cardiomyopathy (HCM), a genetic heart condition with limited treatment options. The company has reaffirmed its ...
Lexicon Pharmaceuticals accelerates partnerships with patients on innovative therapies
Lexicon Pharmaceuticals reflects on a year marked by significant partnerships and advancements. The company emphasized its sustained commitment to collaborating with patients and advocates, ...
Lexicon Pharmaceuticals to advance obesity treatment with new ACSL5 inhibitor data
Lexicon Pharmaceuticals has unveiled promising preclinical data on its investigational ACSL5 inhibitor, targeting obesity and chronic weight management. The findings were published in the Journal ...
Lexicon Pharmaceuticals backs Type 1 diabetes research ahead of World Diabetes Day
Lexicon Pharmaceuticals recently expressed its support for the Type 1 diabetes community by attending the Breakthrough T1D Promise Gala in New York City. The event, which took place just ahead of ...
Lexicon Pharmaceuticals unveils new data on cardiovascular SGLT1/2 inhibitor
Lexicon Pharmaceuticals is set to present new data regarding their investigational SGLT1/2 inhibitor at the American Heart Association's Scientific Sessions this weekend. The focus of the ...
